comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib

Clicks: 145
ID: 218229
2012
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #151 of 171 articles by views in jurnal tam

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 171 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Fei Xu,1,* Jingxun Wu,2,* Cong Xue,1,* Yuanyuan Zhao,1 Wei Jiang,3 Liping Lin,4 Xuan Wu,5 Yachao Lu,6 Hua Bai,7 Jiasen Xu,8 Guanshan Zhu,6 Li Zhang11State Key Laboratory of Oncology in South China, Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, People's Republic of China; 2Department of Medical Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, People's Republic of China; 3Department of Medical Oncology, Cancer Hospital of Guangxi Medical University and Guangxi Autonomous Regional Cancer Hospital, Nanning, Guangxi, People's Republic of China; 4Department of Oncology and Hemotology, Panyu Central Hospital, Guangzhou, Guangdong, People's Republic of China; 5Department of Chemotherapy, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, People's Republic of China; 6Innovation Center China, AstraZeneca Global R&D, Shanghai, People's Republic of China; 7Department of Thoracic Medical Oncology, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing, People's Republic of China; 8SurExam Bio-Tech Co, Ltd, Science City, Guangzhou, People's Republic of China *These authors contributed equally to this workBackground: Previous studies have reported that epidermal growth factor receptor (EGFR) mutation in tumor tissue and peripheral blood can predict the response to EGFR tyrosine kinase inhibitor (TKI) in non-small cell lung cancer (NSCLC). However, the heterogeneity of the sample sources makes it difficult to evaluate the detecting methodologies. The goal of this study is to compare different methods for analyzing EGFR mutation in blood and tumor tissue.Materials and methods: Fifty-one advanced NSCLC patients treated with gefitinib were included in the study. The EGFR mutation status of each patients' blood was analyzed by denaturing high-performance liquid chromatography (DHPLC), mutant-enriched liquidchip (ME-Liquidchip), and Scorpion Amplification Refractory Mutation System (Scorpion-ARMS) kits. EGFR mutation information in paired tumor samples detected by Scorpion-ARMS served as a reference. Comparative analyses were performed on mutation status results obtained from different methods and on the association between the clinical outcome of TKI treatment and EGFR mutation status.Results: The response rate (RR) in the whole group was 33.3%. EGFR mutation rates were identified as 15.7%, 27.5%, and 29.4% by DHPLC, ME-Liquidchip, and Scorpion-ARMS in blood, respectively. In 34 cases that had paired tumor samples, the mutation rate in tissue was 41.2%. The RRs of patients with mutation detected by different methods were 71.4% (tumor), 62.5% (blood, DHPLC), 50.0% (blood, ME-Liquidchip), and 66.7% (blood, Scorpion-ARMS). EGFR mutation detected by Scorpion-ARMS in blood and tumor tissues had better prediction of RR to EGFR-TKI (P = 0.002 and P = 0.001) than mutation detected with DHPLC and ME-Liquidchip.Conclusion: Tumor tissue sample is the best source for EGFR mutation analysis in NSCLC patients. Peripheral blood samples may be used as an alternative source only in special conditions. Scorpion-ARMS, DHPLC, or ME-Liquidchip methods are all optional for detecting tumor EGFR mutation from blood.Keywords: non-small cell lung cancer, EGFR mutation, mutation detection methods, gefitinib
Reference Key
f2012oncotargetscomparison Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Xu F;Wu J;Xue C;Zhao Y;Jiang W;Lin L;Wu X;Lu Y;Bai H;Xu J;Zhu G;Zhang L
Journal jurnal tam
Year 2012
DOI
DOI not found
URL
http://www.dovepress.com/comparison-of-different-methods-for-detecting-epidermal-growth-factor--a11725
Keywords
neoplasms Oncology including cancer and carcinogens tumors

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.